The role of VEGFR-1 is further complicated by the presence of VEGF-B and placental growth factor (PlGF), both of which bind to VEGFR-1 but not VEGFR-2. 20, 21 Neither VEGF-B nor PlGF is critical for vascular development, but both seem to promote angiogenesis in ischemic adult tissues. [22] [23] [24] Such findings imply that VEGFR-1 kinase signaling may have a role in stimulating angiogenesis. Nonetheless, precise interpretation of these findings is difficult for a number of reasons. First, because VEGF-A, VEGF-B, and PlGF all bind to VEGFR1, the lack of a particular ligand is unlikely to cause a total loss of VEGFR-1 signaling. Second, excess VEGF-B or PlGF may have the potential of displacing VEGF-A from VEGFR-1, leading to increased VEGF-A bioavailability to VEGFR-2. Third, VEGFR-1 and VEGFR-2 are known to form heterodimers, likely in a PlGF/VEGF-Adependent manner. 25 These complexities raise the possibility that VEGF-B or PlGF deficiency may affect both VEGFR-1 and VEGFR-2 signaling. Because of these complications, the precise role of VEGFR-1 in postnatal and adult tissues remains ambiguous. In the present study, we report that VEGFR-1 knockout in postnatal and adult mice led to increased angiogenesis, which is accompanied by enhanced VEGF-A bioavailability to VEGFR-2, substantially increased VEGFR-2 protein abundance, and elevated VEGFR-2 downstream signaling.
Methods

Mice
All procedures used in handling mice were approved by the Animal Care Committee at the University of Connecticut Health Center in compliance with Animal Welfare Assurance. Engineering of Vegfr-1 allele with floxed exon 3 (Vegfr-1 flox ) is described in Materials in the online-only Data Supplement. Vegfr-1 floxed mice were crossed with Rosa26Cre ERT2 mice for tamoxifen-inducible knockout in a broad range of tissues. Rosa26Cre ERT2 was activated by oral gavage of tamoxifen (Sigma; 20 mg/mL in corn oil) at 100 g daily from postnatal day 1 (P1) through P4 in neonatal mice for analyses at or before P21 or at 3 mg every other day for a week at 7 weeks of age for analyses in adult mice. Genotyping of mice was performed with the use of primers listed in Table I in the online-only Data Supplement.
Molecular Analyses
All reverse transcription polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR primers are listed in Tables II and III in the online-only Data Supplement, respectively. Quantitative realtime RT-PCR was performed with the use of SYBR Green PCR master mix (Applied Biosciences) and an ABI PRISM 7900HT Sequence Detection System.
For Western blotting, VEGFR-2 was immunoprecipitated from brain tissue lysates of P21 mice with the use of anti-VEGFR-2 (AF644; R&D Systems) and analyzed by Western blotting with the use of anti-phosphotyrosine antibody (4G10; Millipore) and anti-VEGFR-2 (55B11; Cell Signaling Technology). In addition, total brain lysates were analyzed by Western blotting with the use of the following antibodies: anti-VE-cadherin (C-19), anti-phospho-ERK (E-4), and anti-ERK (C-14) (all from Santa Cruz Biotechnology), anti-phospho-Akt (Ser473, Cell Signaling Technology), and anti-Akt (BD Biosciences). Quantification of band intensities was performed with the aid of National Institutes of Health ImageJ. More details are provided in Materials in the online-only Data Supplement.
Immunohistochemical and Immunofluorescence Staining
Tissues were fixed overnight in 4% paraformaldehyde at 4°C and processed for either frozen or paraffin sectioning. Anti-platelet/ endothelial cell adhesion molecule (PECAM)-1 (MEC13.3; BD Pharmingen) and biotinylated secondary antibodies were used with ABC and DAB kits (Vector Laboratories).
Retinas were isolated from fixed eyes, flat-mounted by 4 incomplete radial incisions, and stained with Ն1 of the following reagents: isolectin B 4 conjugated to Alexa Fluor-594 (IB 4 -Alexa 594), IB 4 -Alexa 488 (Invitrogen), anti-␣-smooth muscle actin conjugated to fluorescein isothiocyanate (Sigma-Aldrich), anti-NG2 (Millipore), and goat anti-rabbit conjugated to Alexa Fluor-488 (Invitrogen). Stained retinas were visualized with the use of either the Zeiss Pascal or Zeiss 510 confocal microscope system. Three-dimensional imaging was performed with IMARIS software (Bitplane).
For perfusion staining of retinas, fluorescein isothiocyanate-RCA I lectin (Vector Laboratories) was injected into the left ventricle of anesthetized mice (100 g per mouse). After 2 minutes, mice were perfused with phosphate-buffered saline containing 1% bovine serum albumin, followed by perfusion fixation with 4% paraformaldehyde for 5 minutes. Subsequently, retinas were isolated and stained with IB 4 -Alexa 594.
BrdU Assay and Identification of Tip Cells
P21 mice were injected with 5-bromo-2Ј-deoxyuridine (BrdU) (Roche) intraperitoneally at 0.12 g/kg body wt, and retinas were isolated and processed for anti-BrdU (1:300; Becton Dickinson) immunofluorescence staining as described previously. 26 Tip cells were identified as described by Gerhardt et al. 27 Briefly, P5 retinas were double stained with IB 4 -Alexa 594 and SYTOX green, and 6-m z-stack images were taken. Tip cells were identified as IB 4 -Alexa 594 -positive cells at the vascular front, with filopodia extensions, and containing SYTOX-positive nuclei.
Vascular Permeability Assays
For permeability assay in P21 mice, 100 L of a sonicated and filtered 0.5% solution of Evans blue dye (EB) (Sigma) was injected via the tail vein. After 4 hours, mice were euthanized and perfused with phosphatebuffered saline. Tissues were collected, minced, dried at 55°C overnight, and weighed. EB was extracted with formamide and quantified by absorbance at 620 nm.
For Miles assay, 7-week-old mice were treated with tamoxifen. At 8 weeks of age and 48 hours before EB injection, tamoxifen-treated mice were shaved and depilated with Nair on the back. EB (0.5%) was injected at 100 L per mouse via the tail vein, with or without intraperitoneal injection of SU1498. Twenty minutes afterward, mice were injected intradermally with VEGF 164 (R&D Systems) at 3 different concentrations (5 ng/mL, 50 ng/mL, and 1.25 g/mL) or with mock solution (phosphate-buffered saline containing 0.1% bovine serum albumin). At 30 minutes after VEGF-A or mock injection, mice were euthanized, skin tissues were dissected from areas of injection, and EB extravasation was analyzed.
Intraocular Injections
P4 mice were anesthetized, and intraocular injections of 1 L of anti-VEGF-A (1 g/L; Cedarlane) or phosphate-buffered saline were performed with a 10-L gas-tight syringe (Hamilton) outfitted with a custom-tip 33-gauge needle (Hamilton).
Pharmacological Inhibition of Angiogenesis
From P7 to P20, mice were treated by daily intraperitoneal injection of 100 L SU1498 (100 mmol/L in dimethyl sulfoxide; Sigma) or dimethyl sulfoxide alone. At P21, mice were euthanized, and retinas were isolated and stained with IB 4 -Alexa 594. mice in each group were fed tamoxifen at 7 weeks of age (3 doses over 1 week at 3 mg per dose). At 24 hours after the last dose of tamoxifen treatment, all tamoxifen-treated mice (8 weeks of age) were subject to LAD ligation. Myocardial infarction was assessed by Masson trichrome staining of serial heart cross sections. Infarct sizes were calculated as the ratio of the sum of all infarct lengths to total endocardial and epicardial circumferences per heart, which was measured with the use of ImagePro Plus 5.1 software.
Statistical Analysis
Statistical analysis was performed with the use of GraphPad InStat software. Analyses from the Mann-Whitney test, one-way ANOVA, or t test are indicated where appropriate. Data are presented as meanϮSD. P values Ͻ0.05 were considered statistically significant. Vegfr-1 ⌬/⌬ neonatal mice were viable although smaller than floxed littermates (at P21, Vegfr-1 flox/flox mice were 8.34Ϯ1.2 g; Vegfr-1 ⌬/⌬ mice were 5.74Ϯ0.8 g; nϭ15 for each genotype; PϽ0.0001, Mann-Whitney test). Vegfr-1 ⌬/⌬ adult mice, which were treated with tamoxifen at 7 weeks, were not visibly different from wild-type or floxed mice and lived for Ͼ2 years.
Results
Angiogenesis in Postnatal and Adult Tissues
We initially evaluated angiogenesis using P21 retinas after tamoxifen treatment at P1 to P4. Staining with IB 4 -Alexa 594 revealed increased angiogenesis ( Figure 1B through 1G ). In the inner plexiform layer (IPL), the percentage of vascularized areas (defined as the percentage of a 0.5-mm 2 tissue area occupied by vascular structures) increased from 10.9Ϯ2.3% in Vegfr-1 flox/flox mice to 25.6Ϯ3.8% in Vegfr-1 ⌬/⌬ mice ( Figure 1B) . Similarly, the number of branching points (points at which 2 vessels are joined) also increased significantly in Vegfr-1 ⌬/⌬ mice ( Figure 1C ). In the IPL, Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice had 69.4Ϯ8.9 and 202.4Ϯ26.8 branch points per 0.5-mm 2 area, respectively. Similar observations were made in the outer plexiform layer (OPL) ( Figure 1B and 1C ). In addition, vascularization was also apparently increased in the retinal tissue between the IPL and the ganglion cell layer ( Figure 1F and 1G). Loss of Vegfr-1 in adults also led to increased angiogenesis in the IPL and OPL, although increase in the ganglion cell layer was insignificant ( Figure 1H through 1M and Figure IIIA in the online-only Data Supplement).
Increased angiogenesis was also observed in other tissues of Vegfr-1 ⌬/⌬ mice at P21, including the lung, heart, brain, kidney, and liver. As examples, anti-PECAM-1-stained heart and brain sections and quantification of vascular lumens are shown in Figure 1N through 1U, which demonstrates an increased number of vascular lumens per equivalent area. We also quantified the number of vascular lumens per cardiomyocyte and confirmed increased capillary-to-cardiomyocyte ratio in P21 Vegfr-1 ⌬/⌬ mice ( Figure IIIC 
Vascular Maturation, Perfusion, and Permeability
Vascular maturation was examined in P21 retinas by anti-␣smooth muscle actin staining for vascular smooth muscle cells (Figure 2A and 2B) and anti-NG2 staining for mural cells ( Figure 2C and 2D and Figure IVA through IVD in the online-only Data Supplement). In both experiments, no apparent differences were found between Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice. Although there were more retinal arterioles in VEGFR-1-deficient mice, the number of venules also increased proportionally, and the paired arrangement of arterioles and venules was not affected (Figure 2A Vascular permeability was assayed by monitoring extravasation of intravenously injected EB in several different tissues, including brain, lung, liver, heart, and retina. Extravasation of EB varied greatly among different tissues independent of Vegfr-1 genotypes ( Figure 2G ), which is a reflection of intrinsic properties of different tissues. For the same tissue type, however, extravasation of the dye was comparable between Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice ( Figure 2G ).
Angiogenesis in Ischemic Myocardial Tissues
We performed ligation of the LAD to induce infarction in 8-week-old male mice and then monitored cardiac performance periodically by echocardiography. Echocardiographic ments of Vegfr-1 ⌬/⌬ mice at 4 weeks after ligation showed statistically significant differences from floxed controls, these differences were abated by 8 weeks after ligation ( Figure VG and VH in the online-only Data Supplement).
At 8 weeks after LAD ligation, we examined infarct size and angiogenesis in Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice. Quantification of trichrome-stained heart sections indicated that in Vegfr-1 ⌬/⌬ mice, infarct size was reduced by approximately 35% compared with floxed mice ( Figure 3A through 3C), accompanied by an increased number of PECAM-1positive vessels ( Figure 3D through 3H) . Per 150ϫ100-m 2 area in the border zone, Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice had 46.3Ϯ4.7 and 80.5Ϯ19.9 vessels, respectively ( Figure  3D through 3F) . A similarly significant increase was also observed in noninfarcted areas (Figure 3D , 3G, and 3H).
We also quantified angiogenesis in cardiac tissues by normalizing the number of IB 4 -positive vessels to cardiomyocytes at 8 weeks after ligation. Despite modestly increased cardiomyocyte numbers, Vegfr-1 ⌬/⌬ mice had higher capillary-to-cardiomyocyte ratios than floxed controls, which confirmed increased angiogenesis ( Figure VI VEGFR-1 is thought to mediate monocyte and macrophage migration and infiltration. 18, 30 Therefore, we examined macrophage infiltration into ischemic myocardium by staining heart sections from LAD-ligated mice for F4/80-positive cells. In both Vegfr-1 ⌬/⌬ and floxed mice, similar numbers of F4/80-positive macrophages were present in infarcted myocardium ( Figure VIID 
Cellular and Molecular Analyses
We analyzed incorporation of intraperitoneally injected BrdU into retinal endothelial cells in P21 mice. In Vegfr-1 flox/flox retinas, anti-BrdU and IB 4 -Alexa 594 staining revealed few double-positive cells ( Figure 4A through 4C) . In Vegfr-1 ⌬/⌬ retinas, double-positive cells were more frequently detected ( Figure 4D through 4F ). In ganglion cell layer blood vessels, for example, the number of BrdU-positive cells increased from 0.4Ϯ0.4 per 2-mm 2 area in Vegfr-1 flox/flox retinas to 13.6Ϯ4.0 in Vegfr-1 ⌬/⌬ retinas ( Figure 4G ). Similar increases were found in both the IPL and OPL vascular layers.
We also examined whether VEGFR-1 deficiency affected tip cell formation. Within the developing vascular plexus in the ganglion cell layer of normal retinas, endothelial tip cells are easily observed between P4 and P6. After neonatal Vegfr-1 knockout, Vegfr-1 ⌬/⌬ retinas exhibited increased abundance of tip cells by P5 ( Figure 4H through 4K ). Per 0.2-mm 2 area, Vegfr-1 ⌬/⌬ retinas had 5.8Ϯ2.2 tip cells in contrast to 4.0Ϯ0.8 tip cells in Vegfr-1 flox/flox retinas ( Figure 4L) .
Quantitative real-time RT-PCR was performed to determine relative mRNA levels of VEGF-A, Flk-1/VEGFR-2, neuropilin-1, neuropilin-2, Notch-1, VEGF-B, angiopoetin-1, PECAM-1, Tek/Tie-2, PlGF, Notch-4, and Delta-like ligand 1, but no significant difference was found between Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ retinas ( Figure 5A and 5B ). Next we investigated whether Vegfr-1 ⌬/⌬ mice displayed any changes over Vegfr-1 flox/flox mice at the protein and signaling levels, including VEGFR-2 Figure 5A ). VEGFR-2 protein increase was not accompanied by similar increases in VE-cadherin, which is also predominantly expressed in endothelial cells. Consistent with increased VEGFR-2 protein abundance and activation, S473-phospho Akt and phospho ERK levels were increased by 51.1% (Figure 5E and 5F) and 64.5% ( Figure 5G and 5H) , respectively.
Role of Increased VEGFR-2 Signaling in VEGFR-1-Deficient Mice
Increased VEGFR-2 abundance and the associated increase in downstream signaling prompted us to test whether angiogen- esis in Vegfr-1 ⌬/⌬ mice could be suppressed by inhibiting VEGFR-2 kinase activity. Therefore, we injected VEGFR-1deficient and floxed mice with VEGFR-2 inhibitor SU1498. 31 After daily injections from P7 to P20, mice were analyzed for angiogenesis at P21. SU1498 diminished angiogenesis in Vegfr-1 ⌬/⌬ retinas, whereas vehicle (dimethyl sulfoxide) alone did not ( Figure 6A through 6J ). In the OPL in particular, SU1498 rescued angiogenesis in Vegfr-1 ⌬/⌬ mice to a level indistinguishable from that of similarly treated floxed controls (Pϭ0.233; Figure 6J ). Interestingly, at the dose level employed in the experiment, SU1498 had little effect on angiogenesis in floxed controls, suggesting that angiogenesis in VEGFR-1-deficient mice depended on elevated VEGFR-2 downstream signaling.
To assess whether VEGFR-2 accumulation is dependent on VEGFR-2 signaling, we examined VEGFR-2 abundance in SU1498-treated and vehicle (dimethyl sulfoxide)-treated Vegfr-1 ⌬/⌬ mice by Western blotting of brain lysates. We found that SU1498 but not vehicle treatment significantly reduced VEGFR-2 protein abundance ( Figure 6K and 6L) . A similar observation was made for phospho-Akt ( Figure 6M  and 6N) . Thus, VEGFR-2 accumulation is at least partially dependent on VEGFR-2 signaling. The incomplete rescue of normal VEGFR-2 and phospho-Akt levels may be due to incomplete inhibition of VEGFR-2 or the existence of VEGFR-2-independent mechanisms.
Whereas SU1498 most strongly inhibits VEGFR-2, it may weakly inhibit other kinases as well. To more specif- ically define the role of VEGFR-2 in angiogenesis in Vegfr-1 ⌬/⌬ mice, we took a genetic approach. Specifically, we asked whether loss of 1 Vegfr-2 wild-type allele in Vegfr-1 ⌬/⌬ background would diminish the difference between Vegfr-1 ⌬/⌬ and floxed mice. To this end, we generated Vegfr-1 flox/flox /Vegfr-2 ϩ/Ϫ /Rosa CreERT2/ϩ mice from Vegfr-1 flox/flox /Rosa CreERT2/ϩ and Vegfr-2 ϩ/Ϫ mice. 14 Figure 7Y ) but increased in the brain and liver (PϽ0.05; Figure 7Z and 7AЈ). As with SU1498 injection, loss of one Vegfr-2 wild-type allele reduced angiogenesis only in mice deficient for VEGFR-1.
VEGF-A Dependence of Angiogenesis and Vascular Permeability Phenotypes in VEGFR-1-Deficient Mice
To directly determine whether increased angiogenesis in VEGFR-1-deficient mice was VEGF-A dependent, we performed intraocular injection of anti-VEGF-A antibody to sequester endogenous VEGF-A and analyzed tip cell formation in early retinas. Statistically significant inhibition of tip cell formation was observed only in Vegfr-1 ⌬/⌬ retinas (Figure 8A through 8I ).
Next we performed Miles assay to quantify vascular permeability induced by exogenous VEGF-A. At the lower concentrations of VEGF-A tested (5 and 50 ng/mL), there was little difference between Vegfr-1 flox/flox and Vegfr-1 ⌬/⌬ mice. At the highest VEGF-A concentration (1.25 g/mL), Vegfr-1 ⌬/⌬ mice showed elevated vascular permeability (Figure 8J) . Overall, these findings demonstrate that VEGFR-1 deficiency rendered blood vessels more sensitive to VEGF-A stimulation. To determine whether increased vascular permeability in Vegfr-1 ⌬/⌬ mice was VEGFR-2 dependent, we combined the Miles assay with SU1498 treatment. Although SU1498 did not affect vascular permeability induced by 5 or 50 ng/mL of VEGF-A ( Figure 8J ), at the highest concentration of VEGF-A (1.25 g/mL), SU1498 reduced vascular permeability significantly in Vegfr-1 ⌬/⌬ mice but only insignificantly in floxed mice ( Figure 8J ).
Discussion
A major finding in this study is that Cre-loxP-mediated Vegfr-1 knockout led to increased angiogenesis in a broad range of neonatal and adult tissues. The vasculature in VEGFR-1-deficient mice displayed the typical hierarchy of large and small blood vessels and retained the ability to recruit pericytes and vascular smooth muscle cells, and peripheral blood vessels appeared to be well connected to the main circulation. Additionally, vascular integrity was unaffected, as shown by similar levels of EB extravasation in both floxed controls and Vegfr-1 knockout mice. These findings suggest that VEGF-A/VEGFR-1 interaction may be a promising target for angiogenesis therapy.
In the mouse LAD model, VEGFR-1 deficiency led to more active angiogenesis and smaller infarct size. It is not clear why reduced infarct size was not accompanied by improved cardiac performance. However, VEGFR-1 may play a role in cardiomyocytes. 32 Thus, cardiac performance in LAD-ligated VEGFR-1-deficient mice may be influenced not only by reduced infarct size but also by a defective compensatory mechanism in cardiomyocytes. In the future, it will be important to directly investigate how cardiomyocytes are affected by cell lineage-specific knockout of Vegfr-1.
VEGFR-1 kinase signaling is known to mediate monocyte/ macrophage migration. 18, 30 However, macrophage infiltration into ischemic myocardium was not significantly affected by VEGFR-1 deficiency. We speculate that macrophage infiltration in VEGFR-1-deficient mice may be affected by two opposing events: more active angiogenesis, which may favor macrophage infiltration due to increased endothelium surface area, and VEGFR-1 signaling deficiency in monocytes/macrophages, which may hinder infiltration. Myeloid-specific knockout of Vegfr-1 will be required to directly address this important issue. In addition, monocytes/macrophages may represent an important cell lineage in which the proangiogenic roles of VEGFR-1 may reside, but the net effect of VEGFR-1 on angiogenesis might depend on relative abundance of soluble and full-length isoforms in a particular tissue context.
In several studies, VEGFR-1 has been implicated in positively regulating angiogenesis. For example, treatment of mice with anti-PlGF or anti-VEGFR-1 may inhibit angiogenesis, whereas exogenous delivery or overexpression of VEGF-B and PlGF promotes vascular growth. 22, 23, 33 Although these findings may suggest a role for VEGFR-1 signaling in promoting angiogenesis, at least some of these data do not directly contradict the notion that VEGFR-1 may operate as a VEGF-A sink. For example, blocking PlGF binding to VEGFR-1 by anti-PlGF might free up more VEGFR-1 molecules, thus allowing them to inhibit angiogenesis by sequestering VEGF-A. On the other hand, overexpressed PlGF might interfere with the binding interaction between VEGF-A and VEGFR-1, a condition that may favor angiogenesis due to increased VEGF-A bioavailability to VEGFR-2. The existence of two VEGFR-1 isoforms may also contribute to the controversy. Because of its lack of signaling domains, sVEGFR-1 most likely works as a VEGF-A sink. 12, 29, 34 On the other hand, the full-length isoform may positively regulate angiogenesis through VEGFR-2-independent signaling and VEGFR-1/VEGFR-2 heterodimerization. 35 Notably, although VEGFR-2 tyrosine phosphorylation was not increased at P21, transient increases were detected at an earlier stage. Furthermore, VEGFR-2 downstream signaling was increased, as evidenced by higher levels of phospho-Akt and phospho-ERK. Consistent with a role of VEGFR-2 signaling in elevated angiogenesis, vascular phenotypes in VEGFR-1-deficient mice were fully or partially rescued in different tissues by the VEGFR-2-selective inhibitor SU1498, Vegfr-2 ϩ/Ϫ heterozygosity, or neutralizing anti-VEGF-A antibody.
Taken together, our data indicate that the prevailing function of VEGFR-1 is to inhibit angiogenesis by downregulating VEGFR-2 abundance and signaling. However, VEGFR-2-independent mechanisms are also possible and may operate along with VEGFR-2-dependent mechanisms. It is likely that phenotypes reported in this report reflect the net outcome of losing a strongly antiangiogenic function carried by sVEGFR-1 and a modestly proangiogenic function associated with the full-length isoform. In future studies, it will be interesting to determine how deficiency of specific VEGFR-1 isoforms may affect angiogenesis in different disease models.
